Waldenström Macroglobulinemia
Introduction
Waldenström macroglobulinemia (WM) is a rare, indolent B-cell lymphoma and a distinct subset of lymphoplasmacytic lymphoma (LPL). [1] It is characterized by the presence of a monoclonal immunoglobulin M (IgM) gammopathy and an infiltrate of lymphoplasmacytic cells in the bone marrow. [1] Together, WM/LPL accounts for approximately 2% of all non-Hodgkin lymphomas, with an estimated 2,330 new cases diagnosed annually in the United States. [2]
Biological Basis
Recent genome-wide association studies (GWAS) have identified specific genetic susceptibility loci. Two high-risk loci associated with WM/LPL have been identified: rs116446171 at chromosome 6p25.3 and rs117410836 at chromosome 14q32.13. [3] The rs116446171 variant is located near the genes EXOC2, IRF4, and DUSP22. IRF4 is known to play a critical role in plasma cell differentiation, class-switch recombination, and germinal center fate decisions, and is aberrantly downregulated in WM/LPL. [3] DUSP22 modulates immune and inflammatory responses. [3] The rs117410836 variant is located near TCL1, a gene aberrantly expressed in WM tumor samples that enhances B-cell proliferation and survival, contributing to cell transformation through mechanisms like NF-κB activation. [3] Functional studies suggest that the risk allele at 6p25.3 may have functional importance, potentially affecting regulatory elements or a microRNA binding site, leading to increased reporter transcription and cellular proliferation. [3]
Clinical Relevance
Diagnosing WM requires both histopathologic evidence of an LPL infiltrate in the bone marrow and the presence of a monoclonal IgM protein in the serum, adhering to World Health Organization (WHO) criteria. [1] Characterizing the genetic factors influencing susceptibility to WM/LPL is crucial for understanding its etiology, which could lead to improved risk assessment, diagnostic tools, and potentially targeted therapeutic strategies. The identification of these high-risk loci provides valuable insights into the underlying biological mechanisms of this distinctive B-cell lymphoma. [3]
Social Importance
The familial aggregation of Waldenström macroglobulinemia highlights the importance of genetic counseling and screening for individuals with a family history of the disease or related lymphoproliferative disorders. [4] Understanding the genetic predispositions can help inform at-risk individuals and their families, potentially leading to earlier detection or proactive management. Further research into these genetic loci and their functional implications is essential to fully elucidate the disease's mechanisms and improve patient outcomes.
Methodological and Statistical Considerations
The design of the genome-wide association study (GWAS) included an initial discovery stage that oversampled familial cases, a necessary approach for identifying rare, high-risk variants in a less common disease like Waldenström macroglobulinemia (WM). [3] However, this strategy can lead to an inflation of effect sizes, also known as winner's curse, in the discovery phase, potentially overestimating the strength of association for the identified loci. [3] While subsequent replication in a predominantly non-familial cohort helped mitigate this bias, the pronounced effect sizes observed still warrant careful interpretation. Furthermore, despite the identification of two significant loci, other potential susceptibility loci did not replicate, indicating that some initial signals might have been false positives or that their effects are too subtle to detect with current sample sizes. [3]
Pinpointing the exact functional variants and genes responsible for the observed associations remains a significant challenge inherent to GWAS, as the identified single-nucleotide polymorphisms (SNPs) may be in linkage disequilibrium with the true causal variants. [3] For instance, while rs116446171 at 6p25.3 showed strong association, the possibility that another highly linked SNP, such as rs76106586, is the primary driver of the observed effect cannot be entirely excluded. [3] This limitation means that while these loci are strongly associated with WM risk, the precise biological mechanisms through which they exert their influence require further detailed investigation beyond statistical association.
Generalizability and Phenotypic Nuances
A significant limitation concerning the generalizability of these findings is the restriction of the study population to individuals of European ancestry. [3] Strict quality control measures explicitly excluded participants with less than 80% European ancestry, meaning the identified risk loci and their associated effect sizes may not be directly applicable or equally prevalent in other ancestral populations. [3] This limits the broad applicability of these genetic markers for risk prediction or understanding WM etiology across diverse global populations. Additionally, the ascertainment of family history of WM/lymphoplasmacytic lymphoma (LPL) or other B-cell malignancies relied on self-report in the discovery population, even though a subset underwent validation. [3] Self-reported medical history, while practical for large-scale studies, can introduce recall bias, potentially influencing the accuracy of familial aggregation patterns reported by participants.
Unexplained Heritability and Etiological Gaps
Despite the identification of two high-risk susceptibility loci, these variants collectively explain only a modest 4% of the estimated familial risk for WM/LPL. [3] This indicates a substantial proportion of the disease's heritability remains unexplained, suggesting the existence of numerous other genetic factors, potentially with smaller individual effects, or more complex genetic architectures not captured by this study. [3] The "missing heritability" highlights the need for continued research to uncover additional susceptibility loci and understand their combined contributions to WM risk. Furthermore, while genetic factors are crucial, the overall etiology of WM is still not fully understood, with limited knowledge about potential environmental or gene-environment interactions that may influence disease development. [3] Future epidemiological studies are essential to clarify these underlying biological mechanisms and to identify additional susceptibility loci and their interplay with non-genetic factors.
Variants
Genetic variations play a crucial role in determining an individual's susceptibility to complex diseases like Waldenstrom macroglobulinemia (WM), a rare B-cell lymphoma. Two significant high-risk loci have been identified through genome-wide association studies (GWAS), offering insights into the genetic underpinnings of this malignancy. These loci, located on chromosomes 6p25.3 and 14q32.13, harbor specific single nucleotide polymorphisms (SNPs) and genes that influence the risk of developing WM and its precursor, IgM monoclonal gammopathy of undetermined significance (MGUS). [3] These findings highlight the importance of understanding how specific genetic changes can alter cellular pathways involved in B-cell development and immune regulation, thereby increasing disease risk. [3]
The rs116446171 variant, located at chromosome 6p25.3, is a prominent susceptibility locus for Waldenstrom macroglobulinemia, showing a substantial association with an odds ratio of 21.14. [3] This SNP is situated near the EXOC2 (Exocyst complex component 2) and IRF4 (Interferon regulatory factor 4) genes. Functionally, rs116446171 is hypothesized to influence gene expression by altering microRNA (miRNA) binding sites; the common allele (C) is a predicted binding site for miR-378a-5p, while the risk allele (G) creates a binding site for miR-324-3p. [3] The presence of the risk variant has been linked to increased reporter transcription and cellular proliferation in functional studies, suggesting a mechanism by which it might contribute to WM development. IRF4 is a critical transcription factor involved in plasma cell differentiation, class-switch recombination, and germinal center fate decisions, and its expression is often aberrantly downregulated in WM. [3] Additionally, EXOC2 plays a role in cell proliferation and interacts with components of the NF-κ pathway, which is vital for the survival of tumor cells. [3]
Another significant locus for WM risk is marked by rs117410836 on chromosome 14q32.13, with an odds ratio of 4.90. [3] This variant is located near LINC02318, an uncharacterized long non-coding RNA (lncRNA), and members of the TCL (T-cell leukemia) gene family, including TCL6. LncRNAs like LINC02318 are known to regulate gene expression, cytokine production, and various other cellular functions, often implicated in cancer pathogenesis. [3] They can influence pathways such as NF-κB signaling and interact with transcription factors to modulate immune responses. The TCL gene family members, including TCL6, are proto-oncogenes that are frequently involved in lymphoid malignancies, contributing to abnormal cell growth and survival. The rs117410836 variant resides in a repressive chromatin domain, suggesting a potential regulatory role in the expression of nearby genes that could impact B-cell biology and WM development. [3]
The rs179159 variant is found within the SYNE3 gene, which codes for Spectrin Repeat Containing Nuclear Envelope Protein 3. SYNE3 is a member of the nesprin protein family, crucial for maintaining the structural integrity of the nuclear envelope and connecting the nucleus to the cytoskeleton, thereby playing roles in nuclear positioning, cell migration, and mechanotransduction. These cellular processes are fundamental for normal tissue function and can be significantly altered in various cancers, including B-cell malignancies. Genetic variations like rs179159 can potentially impact SYNE3 gene expression or protein function, which in turn could influence cellular stability, growth, or response to internal and external signals, contributing to the complex genetic landscape of diseases like Waldenstrom macroglobulinemia. [3] Understanding the broader genetic contributions, including variants in genes like SYNE3, is essential for a comprehensive view of genetic susceptibility to such malignancies. [3]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs116446171 | IRF4 - EXOC2 | diffuse large B-cell lymphoma central nervous system non-hodgkin lymphoma waldenstrom macroglobulinemia non-Hodgkins lymphoma CD5 antigen-like measurement |
| rs117410836 | LINC02318 - TCL6 | waldenstrom macroglobulinemia |
| rs179159 | SYNE3 | waldenstrom macroglobulinemia |
Defining Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is precisely defined as a distinct subset of lymphoplasmacytic lymphoma (LPL), a rare and chronic B-cell lymphoma. [3] The defining characteristic of WM is the presence of an immunoglobulin type M (IgM) monoclonal gammopathy, which serves as a key operational definition distinguishing it from other lymphoproliferative disorders. [3] This monoclonal gammopathy signifies the abnormal production of a large amount of IgM protein by the cancerous cells, which are a hybrid of lymphocytes and plasma cells.
WM, along with LPL, collectively accounts for approximately 2% of all non-Hodgkin lymphomas, highlighting its rarity within the spectrum of lymphoid malignancies. [2] The clinical significance of this precise definition lies in guiding diagnosis, prognosis, and therapeutic strategies, as the presence of the IgM monoclonal protein is central to both the disease’s pathophysiology and its clinical manifestations, such as hyperviscosity syndrome. Understanding WM as a chronic B-cell lymphoma emphasizes its typically indolent course, although its high heritability underscores the importance of genetic factors in its etiology. [3]
Classification and Diagnostic Frameworks
The classification and diagnostic criteria for Waldenström macroglobulinemia are established by authoritative nosological systems, most notably the World Health Organization (WHO) classification of Tumours of Haematopoietic and Lymphoid Tissues. [3] According to WHO criteria, a definitive diagnosis of WM requires two primary components: the presence of a lymphoplasmacytic lymphoma (LPL) infiltrate in the bone marrow, coupled with a monoclonal immunoglobulin type M (IgM) protein detectable in the serum. [3] This dual requirement ensures a precise categorical distinction, differentiating WM from other B-cell lymphomas and conditions with IgM gammopathy.
In situations where histopathologic criteria for LPL are met but serum protein electrophoresis data, which would confirm the IgM monoclonal protein, are unavailable, the case is classified solely as LPL. [3] This operational definition underscores the necessity of both the cellular infiltrate and the specific serological biomarker for a WM diagnosis. The WHO framework integrates both morphological and immunophenotypic features with clinical and genetic information to provide a comprehensive and standardized approach to classifying these complex hematological malignancies.
Key Terminology and Genetic Associations
Central to the understanding of Waldenström macroglobulinemia (WM) are several key terms and related concepts. Lymphoplasmacytic lymphoma (LPL) is the broader entity, with WM being its IgM-secreting subtype, making LPL a crucial part of WM's nomenclature. [3] Another important related concept is IgM monoclonal gammopathy of undetermined significance (MGUS), which is considered a precursor condition to WM, often identified in relatives of WM patients. [3] Familial aggregation of WM/LPL and other lymphoproliferative disorders is a well-recognized phenomenon, with first-degree relatives showing increased risk. [4]
Significant genetic insights have emerged regarding WM, including the identification of a somatic driver mutation, MYD88 p.L265P, which is present in most cases of WM and serves as a critical biomarker for diagnosis and potential therapeutic targeting. [5] Furthermore, genome-wide association studies (GWAS) have identified high-risk susceptibility loci for WM/LPL, specifically at 6p25.3 (rs116446171) near EXOC2 and IRF4, and at 14q32.13 (rs117410836) near TCL1. [3] These risk alleles, observed at low frequencies in controls but in excess in affected families, provide crucial insights into the genetic etiology and heritability of this malignancy, with IRF4 expression noted to be aberrantly downregulated in WM/LPL. [6] Genes like TCL1 are also implicated in B-cell proliferation and survival. [3]
Signs and Symptoms of Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, chronic B-cell lymphoma that is specifically categorized as a subset of lymphoplasmacytic lymphoma (LPL) ([3] ). It accounts for approximately 2% of all non-Hodgkin lymphomas, with an estimated 2330 new cases diagnosed annually in the United States ([2] ). The clinical presentation and diagnosis of WM are multifaceted, relying on a combination of histopathological, serological, and increasingly, genetic findings.
Defining Clinical Presentation and Diagnostic Criteria
The clinical presentation of Waldenström macroglobulinemia is fundamentally characterized by specific pathological and serological findings rather than a unique set of initial patient-reported symptoms. According to World Health Organization (WHO) criteria, WM is defined by the presence of a lymphoplasmacytic lymphoma infiltrate in the bone marrow, coupled with a monoclonal immunoglobulin type M (IgM) protein in the serum ([1], [3] ). These objective diagnostic tools, including bone marrow biopsy and serum protein electrophoresis, are critical for confirming the disease and distinguishing it from other lymphoproliferative disorders. When histopathologic criteria for LPL are met but serum protein electrophoresis data are not available, the case is classified as LPL, highlighting the importance of comprehensive assessment ([3] ). The detection of IgM monoclonal gammopathy is a hallmark of WM, and its precursor condition, IgM monoclonal gammopathy of undetermined significance (MGUS), is recognized in the disease spectrum ([3] ).
Genetic Susceptibility and Molecular Markers
The understanding of Waldenström macroglobulinemia is significantly enhanced by identifying key genetic and molecular markers, which provide insights into its etiology and aid in diagnostic understanding. A crucial somatic driver mutation, MYD88 p.L265P, is found in the majority of WM cases and plays a role in the survival of lymphoplasmacytic cells by activating Bruton tyrosine kinase ([5], [7] ). This molecular finding serves as an important biomarker for diagnostic confirmation and may inform therapeutic strategies. Beyond somatic mutations, two high-risk germline susceptibility loci have been identified: rs116446171 located at 6p25.3 (near EXOC2 and IRF4) and rs117410836 at 14q32.13 (near TCL1) ([3] ). These risk alleles, while present at low frequencies in controls, are significantly enriched in affected WM cases, contributing to the inter-individual variation in disease susceptibility ([3] ). Functional studies indicate that the 6p25.3 risk allele may have functional importance, leading to increased reporter transcription and proliferation in transduced cells, thereby suggesting its role in disease pathogenesis ([3] ). The IRF4 gene, situated near rs116446171, is known for its diverse functions in B-cell differentiation, pointing to a potential pathway involved in WM development ([8] ).
Causes of Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, chronic B-cell lymphoma characterized by the presence of an immunoglobulin type M (IgM) monoclonal gammopathy. It represents a subset of lymphoplasmacytic lymphoma (LPL) and accounts for approximately 2% of all non-Hodgkin lymphomas, with an estimated 2330 new cases diagnosed annually in the US. [2] The etiology of WM is complex, involving a combination of genetic predispositions, somatic mutations, immune system dysregulation, and potentially environmental factors.
Genetic Predisposition and Inherited Risk
A strong familial component contributes to the risk of developing Waldenström macroglobulinemia, with family history of WM/LPL or related lymphoproliferative disorders significantly associated with increased susceptibility. [4] First-degree relatives of affected individuals face an elevated risk, and research indicates that familial aggregation patterns can influence the characteristics of the disease. [9] Genome-wide association studies (GWAS) have identified specific inherited genetic variants that confer a higher risk for WM/LPL. Two prominent high-risk susceptibility loci have been identified: rs116446171 on chromosome 6p25.3 and rs117410836 on chromosome 14q32.13. [3]
The rs116446171 variant, located near the genes EXOC2, IRF4, and DUSP22, carries a substantial odds ratio of 21.14, while rs117410836, situated near the TCL1 gene family, has an odds ratio of 4.90. [3] Both risk alleles are found at low frequencies in the general population but are significantly enriched in affected individuals within high-risk families, with 76% and 86% of first-degree relatives with WM or its precursor, IgM monoclonal gammopathy of undetermined significance (MGUS), carrying these respective variants. [3] These two identified loci collectively explain about 4% of the familial risk for WM/LPL, and broader analyses suggest that common single nucleotide polymorphisms (SNPs) could account for approximately 25% of the overall heritability, indicating the existence of additional undiscovered genetic loci. [3] The rs116446171 SNP has also been associated with diffuse large B-cell lymphoma, suggesting shared genetic susceptibility pathways across certain B-cell malignancies. [10]
Somatic Genetic Alterations and B-Cell Biology
Beyond inherited predispositions, somatic genetic mutations play a critical role in the pathogenesis of Waldenström macroglobulinemia. A key driver mutation, MYD88 p.L265P, is found in the majority of WM cases. [5] This somatic mutation enhances the survival of lymphoplasmacytic cells by activating Bruton tyrosine kinase (BTK), which is crucial for B-cell signaling and proliferation. [7] Notably, germline mutations in MYD88 have not been observed in WM, distinguishing this somatic alteration as a primary oncogenic event acquired during an individual's lifetime. [3]
Functional studies of the inherited risk allele at 6p25.3 (rs116446171) demonstrate increased reporter transcription and cellular proliferation in transduced cells, indicating a direct impact on B-cell behavior. [3] The genes near this locus, such as IRF4, are critical for plasma cell differentiation, class-switch recombination, and germinal center fate decisions, and its expression is aberrantly downregulated in WM/LPL. [8] IRF4 also negatively regulates Toll-like receptor (TLR) signaling by interacting with MYD88, highlighting a potential interplay between inherited susceptibility and somatic driver mutations in modulating crucial B-cell pathways. [3]
Epigenetic Modifications and Regulatory Pathways
Epigenetic mechanisms, which involve heritable changes in gene expression without altering the underlying DNA sequence, also contribute to the pathogenesis of WM. For instance, the rs117410836 susceptibility locus on 14q32.13 resides within a repressive chromatin domain marked by histone H3 lysine 27 trimethylation (H3K27me3), an epigenetic modification typically associated with gene silencing. [3] This suggests that altered chromatin states in this region could influence the expression of nearby genes, such as members of the TCL1 family, which are involved in T-cell leukemia and B-cell proliferation. [3]
Furthermore, microRNAs (miRNAs) are implicated in regulatory pathways relevant to WM. For example, hsa-miR-324-3p is shown to induce promoter-mediated expression of the RelA gene, which is a component of the NF-κB pathway. [11] Constitutive activation of NF-κB is a known feature in B-cell lymphoid malignancies, including WM, indicating that epigenetic regulation via miRNAs can contribute to the survival and proliferation of malignant cells. [12] Genes like DUSP22, located near the 6p25.3 locus, also modulate immune and inflammatory responses through the regulation of MAPK pathways, further highlighting the intricate interplay of genetic, epigenetic, and immune factors in WM etiology. [3]
Biological Background of Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, chronic B-cell lymphoma that is a subset of lymphoplasmacytic lymphoma (LPL). [3] It is characterized by the presence of a monoclonal immunoglobulin type M (IgM) gammopathy. [3] This malignancy accounts for approximately 2% of all non-Hodgkin lymphomas, with an estimated 2,330 new cases diagnosed annually in the US. [3] The etiology of WM is not fully understood, but it involves a complex interplay of genetic predispositions, immune dysregulation, and specific molecular pathways. [3]
Cellular Origin and Pathophysiological Hallmarks
Waldenström macroglobulinemia originates from B lymphocytes, specifically affecting cells that exhibit characteristics of both lymphocytes and plasma cells, leading to a lymphoplasmacytic infiltrate predominantly in the bone marrow. [3] These malignant cells undergo uncontrolled proliferation and differentiation, ultimately leading to the overproduction of a monoclonal IgM protein. [3] This excess IgM, known as monoclonal gammopathy, is a defining feature of WM and contributes to many of its clinical manifestations, including hyperviscosity syndrome and organ infiltration. [3] The progression of these abnormal B cells disrupts normal immune function and bone marrow hematopoiesis, leading to various systemic consequences.
Key Genetic Drivers and Intracellular Signaling
A critical somatic driver mutation, MYD88 p.L265P, is found in most cases of Waldenström macroglobulinemia, playing a central role in the disease's pathogenesis. [5] This mutation promotes the survival of lymphoplasmacytic cells by constitutively activating Bruton tyrosine kinase (BTK), which is a key component in B-cell receptor signaling pathways. [7] Beyond MYD88, other signaling pathways are also implicated; for instance, NF-κB activation is frequently observed in B-cell lymphoid malignancies, contributing to cell survival and proliferation. [12] Additionally, DUSP22 modulates immune and inflammatory responses through the regulation of MAPK (mitogen-activated protein kinase) signaling and suppresses IL6/STAT3 signaling, both of which are crucial for cellular growth and inflammatory processes. [13]
Germline Susceptibility and Regulatory Networks
Genetic predisposition is a significant factor in Waldenström macroglobulinemia, with family history of WM/LPL or related lymphoproliferative disorders strongly associated with increased risk. [3] Genome-wide association studies have identified two high-risk susceptibility loci: rs116446171 at 6p25.3 and rs117410836 at 14q32.13. [3] The 6p25.3 locus is near genes such as EXOC2, IRF4, and DUSP22, which are plausible susceptibility genes involved in lymphoid cancers. [3] IRF4 is aberrantly downregulated in WM/LPL and is critical for plasma cell differentiation and germinal center fate decisions, while EXOC2 interacts with Ral proteins and TBK1 to promote cancer cell proliferation and survival. [14] The 14q32.13 locus maps near TCL1 and the uncharacterized long non-coding RNA (lncRNA) LINC02318, with lncRNAs known to regulate transcription, cytokine production, and NF-κB signaling, thereby influencing gene expression programs and innate immune system function. [3]
Immune Dysregulation and Systemic Consequences
Chronic immune stimulation, autoimmunity, and specific infections are recognized as risk factors for Waldenström macroglobulinemia, suggesting a strong link between immune dysregulation and disease development. [15] The IRF4 gene, located near the 6p25.3 susceptibility locus, plays a pivotal role in immune responses by negatively regulating Toll-like receptor (TLR) signaling through its interaction with MYD88. [16] Dysregulation of IRF4 can impair normal B-cell and plasma cell function, contributing to the malignant phenotype. [17] Furthermore, microRNAs, such as miR-324-3p, have been shown to induce the expression of RelA, an NF-κB component, and may contribute to the increased proliferation observed with the 6p25.3 risk allele. [11] These interconnected molecular and cellular mechanisms highlight how disruptions in immune homeostasis and genetic predispositions collectively contribute to the systemic development and progression of WM.
Oncogenic Signaling Cascades and Transcriptional Dysregulation
Waldenström macroglobulinemia (WM) is characterized by a core set of dysregulated signaling pathways that drive malignant B-cell proliferation and survival. A pivotal mechanism involves the somatic MYD88 p.L265P mutation, present in most WM cases, which leads to constitutive activation of downstream signaling. This mutation supports the survival of lymphoplasmacytic cells by activating Bruton tyrosine kinase (BTK) and, consequently, the NF-κB pathway, which is known for its role in B-cell lymphoid malignancies . [5], [7], [12] Beyond MYD88, the EXOC2 gene, located near the rs116446171 susceptibility locus, interacts with Ral GTPases and the NF-κB pathway constituent TBK1, promoting tumor cell survival, proliferation, invasion, and metastasis . [14], [18], [19], [20]
Transcription factor regulation is also critically altered, with IRF4 playing a significant role; this transcription factor is essential for germinal center B-cell differentiation and plasma cell fates . [8], [17] The DUSP22 gene, another locus of interest, modulates immune and inflammatory responses through the regulation of MAPK signaling and suppresses IL6/STAT3 signaling, which can contribute to WM cell growth and survival through MYD88-independent mechanisms, such as Sp1 transactivation . [13], [21], [22] The interplay of these pathways, including receptor activation, intracellular signaling cascades, and transcription factor activity, creates a pro-survival and proliferative environment for WM cells.
Genetic Predisposition and Regulatory RNA Networks
Genetic susceptibility to WM involves specific loci that influence gene expression and cellular regulation through various mechanisms. Two high-risk loci, 6p25.3 (rs116446171) and 14q32.13 (rs117410836), have been identified, with the risk allele at 6p25.3 demonstrating increased reporter transcription and proliferation in functional studies. [3] The rs116446171 variant is located near EXOC2 and IRF4 and resides in the 3' UTR of LOC100421511, impacting binding sites for microRNAs like hsa-miR-324-3p and hsa-miR-378a-5p. [3] Notably, miR-324-3p can induce promoter-mediated expression of the RelA gene, a crucial component of the NF-κB pathway, thereby linking genetic variants to sustained oncogenic signaling. [11]
The 14q32.13 locus, marked by rs117410836, maps closely to LINC02318, a long noncoding RNA (lncRNA). LncRNAs are critical regulatory mechanisms that influence transcription, cytokine production, and other cellular functions in cancer and immune system development. [23] They can influence gene expression programs, including the NF-κB signaling pathway, interact with transcription factors, and are induced via the canonical Toll-like receptor (TLR) pathway . [24], [25], [26] Additionally, the TCL1 gene, located near this locus, shows dysregulated expression patterns in WM and promotes the development of various mature B-cell lymphomas [27] . These genetic predispositions, coupled with alterations in non-coding RNA regulation, contribute to the aberrant gene expression programs characteristic of WM.
Immune System Dysregulation and Pathway Crosstalk
The etiology of WM is closely intertwined with immune-related and inflammatory conditions, indicating significant pathway crosstalk and systems-level integration of immune responses. The MYD88 L265P mutation, a central driver, constitutively activates NF-κB, a pathway fundamental to immune and inflammatory responses . [5], [12] Conversely, IRF4, a transcription factor involved in B-cell differentiation, also negatively regulates Toll-like receptor (TLR) signaling by binding MYD88, suggesting a complex feedback loop in immune signal transduction. [16] Dysregulation in these interactions can lead to chronic immune stimulation, contributing to WM risk. [15]
Further illustrating pathway crosstalk, DUSP22 modulates immune and inflammatory responses by regulating MAPK signaling and suppresses IL6/STAT3 signaling, both of which are critical for controlling inflammation and immune cell function . [13], [21] The EXOC2 gene, influenced by the 6p25.3 risk allele, functions at the intersection of viral exposure and host immune response, further linking genetic susceptibility to environmental and immune triggers. [19] Moreover, lncRNAs, such as LINC02318 near the 14q32.13 locus, can significantly influence immune response genes and are induced by TLR pathways, highlighting how non-coding RNA networks contribute to the overall immune dysregulation observed in WM . [25], [26] These integrated mechanisms underscore how chronic immune activation and dysregulated immune signaling contribute to the pathogenesis of Waldenström macroglobulinemia.
Genetic Predisposition and Pathway Dysregulation
Waldenström macroglobulinemia (WM) is a rare B-cell lymphoma with a notable genetic component influencing its development and cellular characteristics. A significant somatic driver mutation, MYD88 p.L265P, is found in the majority of WM cases, playing a crucial role in disease pathogenesis by activating Bruton tyrosine kinase (BTK) and supporting the survival of lymphoplasmacytic cells. [5] While this mutation is somatic, its presence highlights a critical therapeutic target in WM. Beyond somatic mutations, germline genetic variations also contribute to susceptibility and can influence cellular pathways relevant to drug response.
Genome-wide association studies have identified two high-risk germline loci associated with WM risk: rs116446171 at 6p25.3, located near the EXOC2 and IRF4 genes, and rs117410836 at 14q32.13, near TCL1. [3] Both risk alleles are observed at low frequencies in the general population but are significantly enriched in affected cases within families, with rs116446171 showing a particularly high odds ratio for WM/LPL risk. [3] The gene IRF4, located near rs116446171, is known for its diverse roles in late germinal center B-cell differentiation and has been implicated in the development of other B-cell malignancies, such as chronic lymphocytic leukemia, suggesting its importance in lymphomagenesis. [8]
Influence on Gene Expression and Cellular Proliferation
Specific germline variants can significantly influence gene expression and cellular behavior, thereby modulating the underlying biology of Waldenström Macroglobulinemia and potentially affecting therapeutic efficacy. The rs116446171 variant at 6p25.3, identified as a strong risk factor, has demonstrated functional importance, with in silico evidence suggesting its association with regulatory elements in primary B-cells and lymphoblastoid cell lines. [3] Functional studies have shown that cells transduced with the 6p25.3 risk allele exhibit significantly increased reporter transcription and cellular proliferation, indicating a direct impact on gene regulation and cell growth. [3]
Furthermore, the rs116446171 risk variant may affect a predicted microRNA binding site, specifically interacting with microRNA-324-3p. [3] Experimental data showed that transfection with PremiR-324-3p significantly increased EGFP fluorescence in cells harboring the variant allele compared to the wild type, suggesting that this single nucleotide polymorphism alters the regulatory interaction with microRNA-324-3p. Such alterations in microRNA-mediated gene regulation can lead to dysregulated protein expression, impacting cell survival and proliferation pathways critical to WM, and potentially influencing the pharmacodynamic response to various therapeutic agents.
Frequently Asked Questions About Waldenstrom Macroglobulinemia
These questions address the most important and specific aspects of waldenstrom macroglobulinemia based on current genetic research.
1. My parent had WM; does that mean I'm more likely to get it too?
Yes, if a close family member like a parent has Waldenström macroglobulinemia, your risk can be higher. This is due to "familial aggregation," meaning the disease can run in families. Specific genetic factors have been identified that increase susceptibility for individuals with a family history.
2. Is there a special test my family should get to check for WM risk?
If WM runs in your family, genetic counseling is recommended. While there isn't one simple "screening test" for everyone, understanding your family's genetic predispositions can help assess your risk. This knowledge can lead to earlier detection or more proactive management if you're considered at higher risk.
3. I'm not European; does my background change my risk for WM?
Current major genetic studies on WM have primarily focused on individuals of European ancestry. This means the specific genetic risk factors identified might not be as applicable or prevalent in other ancestral populations. More research is needed to understand WM risk across diverse global populations.
4. Why did I get WM, but my sibling with a similar family history didn't?
Even with shared family history, genetics only explain a modest portion of the overall risk for WM—about 4% of the familial risk. This suggests that many other factors, both genetic and environmental, play a role in who ultimately develops the disease, even among close relatives.
5. What makes some people more susceptible to developing WM in general?
Some people have specific genetic variations that increase their susceptibility. For instance, variants near genes like IRF4 can affect how your immune cells differentiate, while variations near TCL1 can enhance the proliferation and survival of B-cells, making them more prone to transformation.
6. Can my immune system's health affect my risk of getting WM?
Potentially, yes. One of the identified genetic risk variants is located near DUSP22, a gene known to modulate immune and inflammatory responses. This suggests that the way your body handles immune activity and inflammation could play a role in your susceptibility to WM.
7. Do certain genetic factors make my B-cells more likely to become cancerous?
Yes, some genetic variations can increase this likelihood. For example, a high-risk variant is found near the TCL1 gene, which, when aberrantly expressed, can promote B-cell proliferation and survival. This contributes to the transformation of healthy cells into cancerous ones.
8. If genetics only explain a little, what else might increase my risk for WM?
Beyond the identified genetic variants, there's still a significant portion of WM risk that remains unexplained, often referred to as "unexplained heritability." This suggests that other genetic factors, environmental exposures, or even chronic immune stimulation and inflammatory conditions could contribute to your risk.
9. If I have a higher genetic risk, can I do anything to lower my chances?
While specific lifestyle interventions to directly "lower" genetic risk for WM aren't fully established, understanding your genetic predispositions is valuable. This knowledge can improve risk assessment, help with diagnostic tools, and potentially guide more targeted management strategies to better monitor your health.
10. Do my genes affect how serious my WM might be or how it progresses?
The identified genetic factors primarily relate to susceptibility to developing WM. However, some of these variants are near genes that influence cellular proliferation and transformation, like TCL1. Understanding these underlying biological mechanisms could lead to insights into disease progression and the development of more targeted therapeutic strategies in the future.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Swerdlow, S. H. et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues 4th edn. International Agency for Research on Cancer, 2008.
[2] Teras, L. R. et al. "2016 US lymphoid malignancy statistics by World Health Organization subtypes." CA Cancer J. Clin., vol. 66, 2016, pp. 443–459.
[3] McMaster, M. L. et al. "Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia." Nat Commun, 2018, PMID: 30305637.
[4] Altieri, A., Bermejo, J. L., & Hemminki, K. "Familial aggregation of lymphoplasmacytic lymphoma with non-Hodgkin lymphoma and other neoplasms." Leukemia, vol. 19, 2005, pp. 2342–2343.
[5] Treon, S. P. et al. "MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia." N. Engl. J. Med., vol. 367, 2012, pp. 826–833.
[6] Gutiérrez, N. C. et al. "Gene expression profiling of B lymphocytes and plasma cells from Waldenström’s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals." Leukemia, vol. 21, 2007, pp. 541–549.
[7] Yang, G. et al. "A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia." Blood, vol. 122, 2013, pp. 1222–1232.
[8] De Silva, N. S., et al. "The diverse roles of IRF4 in late germinal center B-cell differentiation." Immunological Reviews, vol. 247, 2013, pp. 73–92.
[9] Kristinsson, S. Y. et al. "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenström macroglobulinemia." J. Natl Cancer Inst., vol. 102, 2010, pp. 557–567.
[10] Bassig, B. A. et al. "Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations." Eur. J. Haematol., vol. 95, 2015, pp. 442–448.
[11] Dharap, A., Pokrzywa, C., Murali, S., Pandi, G., & Vemuganti, R. "MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene." PLoS ONE, vol. 8, 2013, p. e79467.
[12] Nagel, D., Vincendiau, M., Eitelhuber, A. C., & Krappmann, D. "Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies." Oncogene, vol. 33, 2014, pp. 5655–5665.
[13] Lang, R., Hammer, M., & Mages, J. "DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response." J Immunol, vol. 177, 2006, pp. 7497–7504.
[14] Chien, Y., et al. "Ral GTPases in tumorigenesis: emerging from the shadows." Exp Cell Res, vol. 319, 2013, pp. 2337–2342.
[15] Koshiol, J., et al. "Chronic immune stimulation and subsequent Waldenström macroglobulinemia." Archives of Internal Medicine, vol. 168, 2008, pp. 1903–1909.
[16] Negishi, H., et al. "Negative regulation of Toll-like-receptor signaling by IRF4." Proc Natl Acad Sci USA, vol. 102, 2005, pp. 15989–15994.
[17] Ochiai, K. et al. "Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4." Immunity, vol. 38, 2013, pp. 918–929.
[18] Bodemann, B. O., & White, M. A. "Ral GTPases and cancer: linchpin support of the tumorigenic platform." Nat Rev Cancer, vol. 8, 2008, pp. 133–140.
[19] Ishikawa, H., Ma, Z., & Barber, G. N. "STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity." Nature, vol. 461, 2009, pp. 788–793.
[20] Kashatus, D. F. "Ral GTPases in tumorigenesis: emerging from the shadows." Exp Cell Res, vol. 319, 2013, pp. 2337–2342.
[21] Sekine, Y., et al. "Regulation of STAT3-mediated signaling by LMW-DSP2." Oncogene, vol. 25, 2006, pp. 5801–5806.
[22] Fulciniti, M., et al. "MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemia." Blood, vol. 123, 2014, pp. 2673–2681.
[23] Adams, B. D., Anastasiadou, E., Esteller, M., He, L., & Slack, F. J. The inescapable influence of noncoding RNAs in cancer. Cancer Research, 75, 5206–5210 (2015).
[24] Huang, W., et al. DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. Nature, 528, 517–522 (2015).
[25] Rapicavoli, N. A., et al. A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics. eLife, 2, e00762 (2013).
[26] Carpenter, S., et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science, 341, 789–792 (2013).
[27] Lemal, R., et al. TCL1 expression patterns in Waldenström macroglobulinemia. Modern Pathology, 29, 83–88 (2016).